Medicenna Therapeutics (MDNA) Emerging Growth Conference 2025 summary

Program updates and clinical progress

• Lead program MDNA11, an IL-2 super-agonist, shows 30%-50% response rates in patients who failed prior immunotherapies.

• MDNA11 is engineered for safety, potency, and extended half-life, allowing dosing every 2-3 weeks.

• Promising results observed in melanoma, MSI-high, and TMB-high patients, with large market potential in the U.S.

• Near-term data readouts for MDNA11, both as monotherapy and in combination with Keytruda, expected by year-end.

• Bispecific program MDNA113, combining IL-2 and anti-PD-1, targets tumors unresponsive to current checkpoint inhibitors.

Pipeline and strategic direction

• MDNA113, a next-generation bispecific, is advancing toward IND-enabling studies and Phase 1/2 trials in the second half of next year.

• Bizaxofusp, ready for Phase 3, doubled survival in Phase 2 and is being positioned for partnership and commercialization.

• Superkine platform leverages directed evolution from Stanford to create improved immunotherapies and bispecifics.

• Focus remains on addressing unmet needs in oncology and expanding into other indications.

Financial and operational highlights

• Market cap is approximately CAD 80 million, with CAD 21 million in cash, funding operations into Q3 next year.

• Insider ownership stands at 22%, and the company is covered by several research analysts.

• Headquarters in Toronto, listed on TSX and OTCQX.